Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic

Frontiers in Chemistry

Volumn 2, Issue OCT, 2014, Pages

  Moreno, Pedro M D ^a   Pêgo, Ana P ^a,b  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antisense; Cancer; Nanomedicine; Oligonucleotides; Therapeutics

Indexed keywords

EID: 84987630012     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00087     Document Type: Article

References (73)

1. Adiseshaiah, P. P., Hall, J. B., and McNeil, S. E. (2010). Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 99-112. doi: 10.1002/wnan.66
2. Agrawal, S., Temsamani, J., Galbraith, W., and Tang, J. (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16. doi: 10.2165/00003088-199528010-00002
3. Alkilany, A. M., and Murphy, C. J. (2010). Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J. Nanopart. Res. 12, 2313-2333. doi: 10.1007/s11051-010-9911-8
4. Badros, A. Z., Goloubeva, O., Rapoport, A. P., Ratterree, B., Gahres, N., Meisenberg, B., et al. (2005). Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 23, 4089-4099. doi: 10.1200/JCO.2005.14.381
5. Barchet, W., Wimmenauer, V., Schlee, M., and Hartmann, G. (2008). Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol. 20, 389-395. doi: 10.1016/j.coi.2008.07.007
6. Bennett, C. F., and Swayze, E. E. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293. doi: 10.1146/annurev.pharmtox.010909.105654
7. Berger, I., Tereshko, V., Ikeda, H., Marquez, V. E., and Egli, M. (1998). Crystal structures of B-DNA with incorporated 2'-deoxy-2'-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability. Nucleic Acids Res. 26, 2473-2480. doi: 10.1093/nar/26.10.2473
8. Bestas, B., Moreno, P. M., Blomberg, K. E., Mohammad, D. K., Saleh, A. F., Sutlu, T., et al. (2014). Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J. Clin. Invest. 124, 4067-4081. doi: 10.1172/JCI76175
9. Brown, D. A., Kang, S. H., Gryaznov, S. M., Dedionisio, L., Heidenreich, O., Sullivan, S., et al. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
10. Chauhan, V. P., Stylianopoulos, T., Boucher, Y., and Jain, R. K. (2011). Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298. doi: 10.1146/annurev-chembioeng-061010-114300
11. Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popovic, Z., Chen, O., Kamoun, W. S., et al. (2012). Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388. doi: 10.1038/nnano.2012.45
12. Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., et al. (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937.
13. Delong, R. K., Nolting, A., Fisher, M., Chen, Q., Wickstrom, E., Kligshteyn, M., et al. (1997). Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 7, 71-77. doi: 10.1089/oli.1.1997.7.71
14. Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., and Iversen, P. L. (2005). In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11, 3930-3938. doi: 10.1158/1078-0432.CCR-04-2091
15. Ding, Y., Jiang, Z., Saha, K., Kim, C. S., Kim, S. T., Landis, R. F., et al. (2014). Gold nanoparticles for nucleic acid delivery. Mol. Ther. 22, 1075-1083. doi: 10.1038/mt.2014.30
16. Dirin, M., and Winkler, J. (2013). Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther. 13, 875-888. doi: 10.1517/14712598.2013.774366
17. Disterer, P., Kryczka, A., Liu, Y., Badi, Y. E., Wong, J. J., Owen, J. S., et al. (2014). Development of therapeutic splice-switching oligonucleotides. Hum. Gene Ther. 25, 587-598. doi: 10.1089/hum.2013.234
18. Eckstein, F. (1967). A dinucleoside phosphorothioate. Tetrahedron Lett. 8, 1157-1160. doi: 10.1016/S0040-4039(00)90656-7
19. Fang, J., Nakamura, H., and Maeda, H. (2011). The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136-151. doi: 10.1016/j.addr.2010.04.009
20. Geary, R. S. (2009). Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol. 5, 381-391. doi: 10.1517/17425250902877680
21. Gekeler, V., Gimmnich, P., Hofmann, H. P., Grebe, C., Rommele, M., Leja, A., et al. (2006). G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16, 83-93. doi: 10.1089/oli.2006.16.83
22. Gokhale, P. C., Zhang, C., Newsome, J. T., Pei, J., Ahmad, I., Rahman, A., et al. (2002). Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res. 8, 3611-3621.
23. Gomes, C. P., Ferreira Lopes, C. D., Duarte Moreno, P. M., Varela-Moreira, A., Alonso, M. J., and Pêgo, A. P. (2014). Translating chitosan to clinical delivery of nucleic acid-based drugs. MRS Bull. 39, 60-70. doi: 10.1557/mrs.2013.314
24. Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., et al. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286, 447-458.
25. Hammond, S. M., and Wood, M. J. (2011). Genetic therapies for RNA mis-splicing diseases. Trends Genet. 27, 196-205. doi: 10.1016/j.tig.2011.02.004
26. Henry, S. P., Templin, M. V., Gillett, N., Rojko, J., and Levin, A. A. (1999). Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol. Pathol. 27, 95-100. doi: 10.1177/019262339902700117
27. Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F. (2000). Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468-479.
28. Hong, D. S., Kurzrock, R., Oh, Y., Wheler, J., Naing, A., Brail, L., et al. (2011). A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 17, 6582-6591. doi: 10.1158/1078-0432.CCR-11-0430
29. Hovingh, K., Besseling, J., and Kastelein, J. (2013). Efficacy and safety of mipomersen sodium (Kynamro). Expert Opin. Drug Saf. 12, 569-579. doi: 10.1517/14740338.2013.793670
30. Iversen, P. L., Copple, B. L., and Tewary, H. K. (1995). Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol. Lett. 82-83, 425-430. doi: 10.1016/0378-4274(95)03572-9
31. Jaaskelainen, I., Peltola, S., Honkakoski, P., Monkkonen, J., and Urtti, A. (2000). A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides. Eur. J. Pharm. Sci. 10, 187-193. doi: 10.1016/S0928-0987(00)00068-3
32. Jain, R. K. (2012). Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 64, 353-365. doi: 10.1016/j.addr.2012.09.011
33. Jang, S. H., Wientjes, M. G., Lu, D., and Au, J. L. (2003). Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-1350. doi: 10.1023/A:1025785505977
34. Juliano, R., Bauman, J., Kang, H., and Ming, X. (2009). Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6, 686-695. doi: 10.1021/mp900093r
35. Juliano, R. L., Ming, X., and Nakagawa, O. (2012). The chemistry and biology of oligonucleotide conjugates. Acc. Chem. Res. 45, 1067-1076. doi: 10.1021/ar2002123
36. Kawai, G., Yamamoto, Y., Kamimura, T., Masegi, T., Sekine, M., Hata, T., et al. (1992). Conformational rigidity of specific pyrimidine residues in tRNA arises from posttranscriptional modifications that enhance steric interaction between the base and the 2'-hydroxyl group. Biochemistry 31, 1040-1046. doi: 10.1021/bi00119a012
37. Kibler-Herzog, L., Zon, G., Uznanski, B., Whittier, G., and Wilson, W. D. (1991). Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res. 19, 2979-2986. doi: 10.1093/nar/19.11.2979
38. Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., et al. (1998). LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630. doi: 10.1016/S0040-4020(98)00094-5
39. Krieg, A. M., Guga, P., and Stec, W. (2003). P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides 13, 491-499. doi: 10.1089/154545703322860807
40. Krieg, A. M., and Stein, C. A. (1995). Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5, 241.
41. Manoharan, M. (1999). 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta 1489, 117-130. doi: 10.1016/S0167-4781(99)00138-4
42. Meidan, V. M., Glezer, J., Amariglio, N., Cohen, J. S., and Barenholz, Y. (2001). Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation. Biochim. Biophys. Acta 1568, 177-182. doi: 10.1016/S0304-4165(01)00216-1
43. Minshull, J., and Hunt, T. (1986). The use of single-stranded DNA and RNase H to promote quantitative "hybrid arrest of translation" of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 14, 6433-6451. doi: 10.1093/nar/14.16.6433
44. Mocanu, J. D., Yip, K. W., Skliarenko, J., Shi, W., Busson, P., Lo, K. W., et al. (2007). Imaging and modulating antisense microdistribution in solid human xenograft tumor models. Clin. Cancer Res. 13, 5935-5941. doi: 10.1158/1078-0432.CCR-06-3085
45. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., et al. (1993). Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
46. Mou, T. C., Gray, C. W., Terwilliger, T. C., and Gray, D. M. (2001). Ff gene 5 protein has a high binding affinity for single-stranded phosphorothioate DNA. Biochemistry 40, 2267-2275. doi: 10.1021/bi002136f
47. Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., et al. (1991). How does RNase H recognize a DNA.RNA hybrid? Proc. Natl. Acad. Sci. U.S.A. 88, 11535-11539. doi: 10.1073/pnas.88.24.11535
48. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., and Jain, R. K. (2000). Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503.
49. Nielsen, P. E., Egholm, M., Berg, R. H., and Buchardt, O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500. doi: 10.1126/science.1962210
50. Nishizaki, T., Iwai, S., Ohtsuka, E., and Nakamura, H. (1997). Solution structure of an RNA.2'-O-methylated RNA hybrid duplex containing an RNA.DNA hybrid segment at the center. Biochemistry 36, 2577-2585. doi: 10.1021/bi962297c
51. Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., et al. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O, 4'-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401-5404. doi: 10.1016/S0040-4039(98)01084-3
52. Pasternak, A., and Wengel, J. (2011). Unlocked nucleic acid-an RNA modification with broad potential. Org. Biomol. Chem. 9, 3591-3597. doi: 10.1039/c0ob01085e
53. Plenat, F., Klein-Monhoven, N., Marie, B., Vignaud, J. M., and Duprez, A. (1995). Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am. J. Pathol. 147, 124-135.
54. Senn, J. J., Burel, S., and Henry, S. P. (2005). Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J. Pharmacol. Exp. Ther. 314, 972-979. doi: 10.1124/jpet.105.084004
55. Seong, J. H., Lee, K. M., Kim, S. T., Jin, S. E., and Kim, C. K. (2006). Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J. Gene Med. 8, 314-323. doi: 10.1002/jgm.848
56. Simoes, S., Filipe, A., Faneca, H., Mano, M., Penacho, N., Duzgunes, N., et al. (2005). Cationic liposomes for gene delivery. Expert Opin. Drug Deliv. 2, 237-254. doi: 10.1517/17425247.2.2.237
57. Srinivasan, S. K., Tewary, H. K., and Iversen, P. L. (1995). Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5, 131-139.
58. Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., et al. (2012). Chemical modification study of antisense gapmers. Nucleic Acid Ther. 22, 344-359. doi: 10.1089/nat.2012.0366
59. Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., Hog, A., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3. doi: 10.1093/nar/gkp841
60. Stessl, M., Marchetti-Deschmann, M., Winkler, J., Lachmann, B., Allmaier, G., and Noe, C. R. (2009). A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. J. Proteomics 72, 1019-1030. doi: 10.1016/j.jprot.2009.06.001
61. Stewart, A. J., Pichon, C., Meunier, L., Midoux, P., Monsigny, M., and Roche, A. C. (1996). Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol. Pharmacol. 50, 1487-1494.
62. Straarup, E. M., Fisker, N., Hedtjarn, M., Lindholm, M. W., Rosenbohm, C., Aarup, V., et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100-7111. doi: 10.1093/nar/gkq457
63. Summerton, J., and Weller, D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195. doi: 10.1089/oli.1.1997.7.187
64. Van Vlerken, L. E., Vyas, T. K., and Amiji, M. M. (2007). Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24, 1405-1414. doi: 10.1007/s11095-007-9284-6
65. Watanabe, T. A., Geary, R. S., and Levin, A. A. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169-180. doi: 10.1089/oli.2006.16.169
66. Watts, J. K., and Corey, D. R. (2012). Silencing disease genes in the laboratory and the clinic. J. Pathol. 226, 365-379. doi: 10.1002/path.2993
67. Webb, M. S., Tortora, N., Cremese, M., Kozlowska, H., Blaquiere, M., Devine, D. V., et al. (2001). Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 11, 155-163. doi: 10.1089/108729001300338681
68. Winkler, J., Stessl, M., Amartey, J., and Noe, C. R. (2010). Off-target effects related to the phosphorothioate modification of nucleic acids. Chem. Med. Chem. 5, 1344-1352. doi: 10.1002/cmdc.201000156
69. Wisse, E., Jacobs, F., Topal, B., Frederik, P., and De Geest, B. (2008). The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193-1199. doi: 10.1038/gt.2008.60
70. Wu, X. A., Choi, C. H., Zhang, C., Hao, L., and Mirkin, C. A. (2014). Intracellular fate of spherical nucleic acid nanoparticle conjugates. J. Am. Chem. Soc. 136, 7726-7733. doi: 10.1021/ja503010a
71. Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., and Anderson, D. G. (2014). Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541-555. doi: 10.1038/nrg3763
72. Zhang, C., Newsome, J. T., Mewani, R., Pei, J., Gokhale, P. C., and Kasid, U. N. (2009). Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol. Biol. 480, 65-83. doi: 10.1007/978-1-59745-429-2_5
73. Zhang, Y., Qu, Z., Kim, S., Shi, V., Liao, B., Kraft, P., et al. (2011). Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther. 18, 326-333. doi: 10.1038/gt.2010.133